CAN
BBLG

Cetera Advisor Networks’s Bone Biologics BBLG Stock Holding History

Cetera Advisor Networks’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7
Closed -$2.2K – 2603
2022
Q4 		$2.2K Buy
+7
New +$3.94K ﹤0.01% 2534

Other funds holding BBLG

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
MWA
MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cetera Advisor Networks's BBLG Position: Q1 2023 in Review

Cetera Advisor Networks sold out of Bone Biologics (BBLG) in Q1 2023, closing a stake of 7 shares — an estimated $2.2K sold.

Cetera Advisor Networks first reported a position in BBLG in Q4 2022 and held it in 1 quarter. The position peaked at $2.2K in Q4 2022. 7 funds tracked by Wall St. Rank hold BBLG as of Q1 2023.

  • Cetera Advisor Networks reported no remaining Bone Biologics position as of Q1 2023 after selling out during the quarter.
  • Cetera Advisor Networks sold 7 Bone Biologics shares in Q1 2023, an estimated $2.2K.
  • Cetera Advisor Networks first reported a position in Bone Biologics in Q4 2022 and held it in 1 quarter.
  • Cetera Advisor Networks's Bone Biologics position peaked at $2.2K in Q4 2022.
  • 7 funds tracked by Wall St. Rank held Bone Biologics as of Q1 2023.

Based on Cetera Advisor Networks's 13F filing for Q1 2023, filed 15 May 2023.